Background Recently, it has been demonstrated that the disturbance of RNA-binding proteins is closely related to the occurrence, progression and prognosis of diseases and cancers. Meanwhile, the role of RBPs in endometrial cancer remains to be explored. Objective To find out the prognostic role of RBPs in endometrial cancer. Methods Unit COX regression analysis, LASSO, multivariate COX regression analysis, Kaplan–Meier survival analysis. Results We obtained endometrial cancer RNA sequencing data and clinical data from TCGA, screened 284 differentially expressed genes that were differentially expressed between cancer tissues and normal tissues, performed functional enrichment analysis on them, and then screened from the differentially expressed genes identified prognostic-related genes (CD3EAP, EPHB6, CIRBP, LTK, ADARB2, RBPMS), developed a prognostic model to examine differences in OS among patients in high- and low-risk cohorts, and constructed a nomogram to predict patient survival rate. Conclusions We use public databases to study that RBPs have certain value in the occurrence and development of endometrial cancer, and can be used as a prognostic marker for endometrial cancer.

Setting：Immune cells played a vital role in the progression of endometrial cancer, whereas immunologic mechanism and clinical prognostic biomarkers remained to be identified. Objective: To explore the landscape of tumor-infiltrating immune cells in endometrial cancer and the correlation between TIICs and EC prognosis. Methods: Data of 530 patients was downloaded from TCGA. CIBERSORTx estimated the abundance of immune cells. Ranked data used Spearman coefficient to measure the relationship between immune cells and clinical characteristics. Univariate COX hazard analysis was performed to explore the relationship between immune cells and clinical outcomes. Lasso regression was used to screen variables. Multivariate regression was performed for stepwise regression variable screening. Univariate and multivariate Independent prognosis analysis was performed to validate the reliability of the multivariate risk model. A nomographic chart was used to grade and assess each patient’s prognosis. Results: 11 type TIICs were increased in cancer tissues(P<0.05). Univariable regression revealed that 5 types TIICs were significantly related with EC prognosis. TTMMD model was constructed via lasso regression and multivariable cox regression. Log-rank was used to perform survival analysis, and the result was presented by Kaplan-Meier curve(p=5.13e-03). The Roc curve was simultaneously fulfilled to validate the model’s accuracy and predictability(AUC=0.676). The Kaplan-Meier curve of the training set was statistically significant(p=3.807e-02). ROC curve replied the feasibility of the model(AUC=0.678). The risk model was an independent factor for predicting EC prognosis(p<0.001). Conclusion: 11 types TIICs were significantly associated with the prognosis of endometrial cancers. The immune-cells-based risk model was reliable for prognosis assessment.

目的 探讨影响早期宫颈癌患者手术后盆腔淋巴囊肿形成的因素.方法 回顾性分析2013年1月至2017年12月164例早期宫颈癌患者根治术后的病历资料,47例术后发生盆腔淋巴囊肿.采用多因素Logistic回归分析影响宫颈癌根治术后盆腔淋巴囊肿的因素.结果 164例宫颈癌患者中术后共47例发生淋巴囊肿(28.66％),发生时间为术后7～336天(中位时间为54天).淋巴囊肿位于右侧盆腔15例,左侧盆腔11例,双侧盆腔21例.淋巴囊肿直径为2.6～12.4 cm.单因素分析结果显示不同手术方式、使用器械、盆腔淋巴结切除范围、术后引流时间和术后是否放疗与盆腔淋巴囊肿发生有关(P<0.05).Logisitic多因素回归分析结果显示,腹腔镜手术(OR=0.415)和术中使用超声刀(OR=0.394)在术后盆腔淋巴囊肿的形成的保护因素(P<0.05);腹主动脉旁淋巴结清扫(OR=2.696)、引流管拔出时间(OR=1.902)与术后放疗(OR=3.245)为术后盆腔淋巴囊肿形成的独立危险因素(P<0.05).结论 盆腔淋巴囊肿为宫颈癌根治术后的常见并发症,通过采取个体化的合理治疗措施有助于使盆腔淋巴囊肿的发生率降低.

Objective To compare the efficacy and safety between liposome-paclitaxel plus carboplatin and paclitaxel plus carboplatin on epithelial ovarian cancer. Methods We randomly divided 198 cases of epithelial ovarian cancer who had undertook at least six chemotherapy circles after operation into two groups: the experimental group were treated with liposome-paclitaxel (175mg/m2)+carboplatin AUC5 and the control group were treated with paclitaxel (175mg/m2)+carboplatin AUC5. One cycle of chemotherapy was 21 days. A strict observation in the efficacy and adverse reactions of two groups was started from the second chemotherapy cycle. Results The total effective rates (CR+PR) in the experimental group and control group were 50.50% vs. 53.60% (P=0.738). There were 22(11.11%) recurrent cases after chemotherapy, among which six patients 6(27.27%) patients in the experimental group and 16(72.72%) patients in the control group (P=0.029). The incidences of allergic reactions, alopecia, nausea, vomiting, diarrhea, leukopenia, thrombocytopenia, hepatic dysfunction in the experimental group were significantly lower than those in the control group (P < 0.05), while there was no significant difference in terms of other adverse reactions (P > 0.05). Conclusion Compared with paclitaxel plus carboplatin group, the efficacy of liposome-paclitaxel plus carboplatin group is equivalent, the recurrence rate is lower in follow-up period, and the incidence of adverse events is significantly lower, including allergic reactions, bone marrow suppression, gastrointestinal reactions and liver dysfunction.